# Dose Finding Study of CHF 4226 for Treating Patients With COPD

> **NCT00605891** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 278 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** carmoterol (CHF 4226)
- **DRUG:** carmoterol (CHF 4226)
- **DRUG:** carmoterol (CHF 4226)
- **DRUG:** salmeterol
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00605891
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605891, "Dose Finding Study of CHF 4226 for Treating Patients With COPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00605891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*